Prostate Cancer Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharma, Bayer, Nymox Pharmaceutical, Merck, Pfizer, Orion, Zenith

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Prostate Cancer pipeline constitutes 140+ key companies continuously working towards developing 150+ Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Prostate Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Prostate Cancer Market.

The Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Prostate Cancer Pipeline Report: https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Prostate Cancer treatment therapies with a considerable amount of success over the years.
• Prostate Cancer companies working in the treatment market are Silenseed LTD, Lantheus, Immunotherapy Pantarhei Oncology, Immunotherapy Pantarhei Oncology, ORCA Therapeutics, Regeneron Pharmaceuticals, edotin Astellas Pharma Inc, Antev, Zenith Epigenetics, POINT Biopharma, Tavanta Therapeutics, Exelixis, Merck & Co, AstraZeneca, Veru Healthcare, Matrix Biomed, RhoVac, and others, are developing therapies for the Prostate Cancer treatment
• Emerging Prostate Cancer therapies in the different phases of clinical trials are- PT-LODER, LNTH-1558,Zona pellucida, ORCA-010, REGN5678, Enfortumab, Teverelix-TFA, ZEN 3694, PNT2002, TAVT-45, Cabometyx, Pembrolizumab, Talazoparib, Capivasertib, VERU-111, MBM-02, Onilcamotide, and others are expected to have a significant impact on the Prostate Cancer market in the coming years.
• In August 2023, Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of twoprimary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) at theprimary analysis.
• In February 2023, Fusion Pharmaceuticals announced the acquisition from RadioMedix, Inc. of the investigational new drug application for an ongoing Phase II clinical trial (the "TATCIST" trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen ("PSMA") expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial will be known as FPI-2265.
• In February 2023, Corbus Pharmaceuticals entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited for development and commercialization of CRB-701 (SYS6002): a novel clinical-stage antibody drug conjugate (ADC) targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC will retain all rights to SYS6002 in the remaining global markets. Clinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors, potentially including lung, breast and prostate cancer.
• In February 2023, BioXcel Therapeutics, Inc.reported full data from its Phase IIa trial of BXCL701, the Company's investigational, oral innate immune activator, in combination with KEYTRUDA (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.
• In January 2023, Onxeo S.A. gave an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first US clinical study site, Next Oncology San Antonio. This phase I/II multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients with recurrent ovarian, breast, and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on previous PARP inhibitor therapy.
• In October 2022, Ayala Pharmaceuticals, Inc. and Advaxis, Inc. entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala's lead program AL102 for the treatment of desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer.
• In October 2022, Janux Therapeutics announced that the first patient had been dosed in Phase I clinical trial of JANX007 in subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) and is the first product candidate utilizing Janux's TRACTr platform to be administered in humans.
• In February 2022, Zenith Epigenetics Ltd. ("Zenith" or the "Company") announced today the dosing of a first patientwith a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb's PD-1 immune checkpoint inhibitor OPDIVOand YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.

Prostate Cancer Overview
Prostate cancer is a type of cancer that develops in the prostate gland, which is a small walnut-shaped gland located below the bladder in men. The prostate gland produces seminal fluid, which nourishes and transports sperm during ejaculatson.

Get a Free Sample PDF Report to know more about Prostate Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Prostate Cancer Drugs Under Different Phases of Clinical Development Include:
• PT-LODER: Silenseed LTD
• LNTH-1558: Lantheus
• Zona pellucida: Immunotherapy Pantarhei Oncology
• ORCA-010: ORCA Therapeutics
• REGN5678: Regeneron Pharmaceuticals
• Enfortumab: vedotin Astellas Pharma Inc
• Teverelix-TFA: Antev
• ZEN 3694: Zenith Epigenetics
• PNT2002: POINT Biopharma
• TAVT-45: Tavanta Therapeutics
• Cabometyx: Exelixis
• Pembrolizumab: Merck & Co
• Talazoparib: Pfizer
• Capivasertib: AstraZeneca
• VERU-111: Veru Healthcare
• MBM-02: Matrix Biomed
• Onilcamotide: RhoVac

Prostate Cancer Route of Administration
Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Prostate Cancer Molecule Type
Prostate Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Prostate Cancer Pipeline Therapeutics Assessment
• Prostate Cancer Assessment by Product Type
• Prostate Cancer By Stage and Product Type
• Prostate Cancer Assessment by Route of Administration
• Prostate Cancer By Stage and Route of Administration
• Prostate Cancer Assessment by Molecule Type
• Prostate Cancer by Stage and Molecule Type

DelveInsight's Prostate Cancer Report covers around 150+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Prostate Cancer product details are provided in the report. Download the Prostate Cancer pipeline report to learn more about the emerging Prostate Cancer therapies at:
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Prostate Cancer Therapeutics Market include:
Key companies developing therapies for Prostate Cancer are - Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, and others.

Prostate Cancer Pipeline Analysis:
The Prostate Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer Treatment.
• Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Prostate Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Prostate Cancer Pipeline Market Drivers
• Rising aging population and high prevalence rate of Prostate Cancer, innovation in drugs and developments in genomics and proteomics, presence of advanced diagnosis techniques are some of the important factors that are fueling the Prostate Cancer Market.

Prostate Cancer Pipeline Market Barriers
• However, problem of over diagnosis, high cost of Prostate Cancer drugs, side-effects associated with treatment and other factors are creating obstacles in the Prostate Cancer Market growth.

Scope of Prostate Cancer Pipeline Drug Insight
• Coverage: Global
• Key Prostate Cancer Companies: Silenseed LTD, Lantheus, Immunotherapy Pantarhei Oncology, Immunotherapy Pantarhei Oncology, ORCA Therapeutics, Regeneron Pharmaceuticals, edotin Astellas Pharma Inc, Antev, Zenith Epigenetics, POINT Biopharma, Tavanta Therapeutics, Exelixis, Merck & Co, AstraZeneca, Veru Healthcare, Matrix Biomed, RhoVac, and others
• Key Prostate Cancer Therapies: PT-LODER: LNTH-1558,Zona pellucida, ORCA-010, REGN5678, Enfortumab, Teverelix-TFA, ZEN 3694, PNT2002, TAVT-45, Cabometyx, Pembrolizumab, Talazoparib, Capivasertib, VERU-111, MBM-02, Onilcamotide, and others
• Prostate Cancer Therapeutic Assessment: Prostate Cancer current marketed and Prostate Cancer emerging therapies
• Prostate Cancer Market Dynamics: Prostate Cancer market drivers and Prostate Cancer market barriers

Request for Sample PDF Report for Prostate Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Prostate Cancer Report Introduction
2. Prostate Cancer Executive Summary
3. Prostate Cancer Overview
4. Prostate Cancer- Analytical Perspective In-depth Commercial Assessment
5. Prostate Cancer Pipeline Therapeutics
6. Prostate Cancer Late Stage Products (Phase II/III)
7. Prostate Cancer Mid Stage Products (Phase II)
8. Prostate Cancer Early Stage Products (Phase I)
9. Prostate Cancer Preclinical Stage Products
10. Prostate Cancer Therapeutics Assessment
11. Prostate Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Prostate Cancer Key Companies
14. Prostate Cancer Key Products
15. Prostate Cancer Unmet Needs
16 . Prostate Cancer Market Drivers and Barriers
17. Prostate Cancer Future Perspectives and Conclusion
18. Prostate Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Prostate Cancer Market https://www.delveinsight.com/report-store/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Prostate Cancer Epidemiology https://www.delveinsight.com/report-store/prostate-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Prostate Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.